ImmunityBio
Maham Rais, Ph.D. is a Scientist I in Translational Immuno-Oncology at ImmunityBio, Inc., since July 2023, focusing on IND-enabling studies to evaluate vaccine efficacy against cancer. Prior to this role, Maham served as a Postdoctoral Research Fellow at Seattle Children's from June 2021 to April 2023, conducting research on vaccine development for infectious diseases under the supervision of Rhea Coler. Maham earned a Ph.D. in Biomedical Sciences from UC Riverside, where the dissertation explored the mechanisms of Fragile X Syndrome. Early career experiences include clinical research work and contributions to various studies in immunology and infectious disease, resulting in multiple publications. Maham holds a Bachelor of Science degree in Cell/Cellular and Molecular Biology from Howard University.
This person is not in any offices
ImmunityBio
4 followers
ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells.